STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Medivir AB (STO:MVIRB) today announces that the Annual Report for 2014 now is available at the company’s website: www.medivir.com.
- 2014 was an important year for Medivir. We created value in the company through our sales successes with OLYSIO® (simeprevir), and hence revenues, both from sales and from royalties. The most important events in 2014 were, without doubt, the global market launch of OLYSIO® and the approval of OLYSIO® as a pharmaceutical for the treatment of chronic HCV in Europe, enabling us to launch it in the Nordic region.
Help employers find you! Check out all the jobs and post your resume.
